Michael is currently Tenured Professor and Chair of the Department of Epidemiology and Biostatistics and Associate Dean for Research Administration at the School of Public Health (SPH) of the SUNY Downstate Medical Center in Brooklyn, New York, a statistical editor for the Journal of the American College of Cardiology (JACC) and JACC: Cardiovascular Interventions, and a member of the Executive Steering Committee of the ODYSSEY OUTCOMES trial of alirocumab. Earlier in his career, Michael was employed by Pfizer, where he was the project statistical lead for atorvastatin and atorvastatin/torcetrapib. In this position, he designed and supported landmark endpoint studies including MIRACL, CARDS, TNT, IDEAL, SPARCL, and ILLUMINATE. Michael has an MS in biostatistics from Harvard School of Public Health and a PhD in biostatistics from New York University.
« Back to Editorial Board
